Considering those putative mechanisms underlying endothelial dysfunction in patients with hyperuricemia, XO inhibitors are expected to ameliorate endothelial function through decreasing the generation of ROS and lowering serum uric acid levels in patients with hyperuricemia. This evidence concerns the gene XDH and endothelial dysfunction.